-- Achieved $479.0 million in AYVAKIT® (avapritinib) global net product revenues in 2024, including $144.1 million in the fourth quarter ---- Anticipate global AYVAKIT net product revenue of approximately $680 million to $710 million in 2025, representing 45% percent year-over-year growth at the midpoint ---- Peak systemic mastocytosis franchise revenue opportunity updated to $4 billion, with AYVAKIT expected to achieve $2 billion in revenue by 2030 ---- AYVAKIT 3-year safety and efficacy results in ISM and ...

Blueprint Medicines (BPMC) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on February 13, 2025, might help the stock move higher if these key numbers are b ...

After reaching an important support level, Blueprint Medicines Corporation (BPMC) could be a good stock pick from a technical perspective. BPMC recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.A golden cross is a technical chart pattern that can signify a potential bullish breakout. It's formed from a crossover involving a security's short-term moving average breaking above a longer-term moving average, with the most ...

CAMBRIDGE, Mass., Feb. 5, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 13, 2025, to report its fourth quarter and full year 2024 financial results and provide a corporate update.To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID 349846. A webcast of the call will also be available under "Events and Pr ...

Shares of Blueprint Medicines (BPMC) rallied 18.2% on Monday driven by investor enthusiasm following the company’s announcement of its 2025 corporate outlook and growth strategy, highlighting plans to build on its established R&D and commercial expertise.Blueprint’s commercial portfolio only comprises its lead drug Ayvakit (avapritinib), an inhibitor of KIT and PDGFRA proteins, which was initially approved in the United States and the EU to treat gastrointestinal stromal tumors in 2020. Later, the drug’s la ...

Blueprint Medicines (BPMC) shares ended the last trading session 18.2% higher at $103.36. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 6.2% loss over the past four weeks.The sudden soaring of the stock price was observed after Blueprint announced its 2025 corporate outlook and growth strategy, highlighting plans to build on its established R&D and commercial expertise. Growth in 2025 is expected to be fuelled by ...

BLU-808 Phase 1 Trial Results - BLU-808 demonstrated rapid, robust, and sustained reductions in serum tryptase, exceeding 80% in the Phase 1 healthy volunteer study [6] - Dose-dependent tryptase reductions were observed: 1 mg (-23%), 3 mg (-41%), 6 mg (-66%), and 12 mg (-87%) [2] - BLU-808 showed a wide therapeutic window and was well-tolerated at all doses tested, with no serious adverse events or discontinuations [7][16] Systemic Mastocytosis Franchise Opportunity - The company estimates the peak revenue opportunity for its systemic mastocytosis (SM) franchise at $4 billion, driven by AYVAKIT's strong launch and evolving SM prevalence estimates [6][15] - AYVAKIT revenue is expected to reach $2 billion by 2030 [6][15] - The company plans to achieve reimbursement for AYVAKYT in ≥20 countries by the end of 2025 [3] Pipeline and Strategic Updates - The company is advancing CDK2 and CDK4 targeted protein degraders, prioritizing further investment in its CDK franchise for breast cancer and other solid tumors [3] - The Phase 3 HARBOR trial of elenestinib, a next-generation KIT D816V inhibitor, has been initiated in patients with indolent systemic mastocytosis (ISM) [3] - Proof-of-concept trials for BLU-808 in chronic urticaria, allergic asthma, allergic rhinitis, allergic conjunctivitis, and mast cell activation syndrome are planned for 2025 [8][20] Financial and Corporate Goals - The company expects AYVAKIT product revenue for full-year 2024 to be $475 to $480 million, representing an increase of more than 130% over 2023 [12] - Corporate goals for 2025 include growing franchise leadership in SM and achieving clinical proof-of-concept for BLU-808 in allergic and inflammatory diseases [20] - The company aims to nominate two development candidates, including its first targeted protein degrader, in the second half of 2025 [17] J P Morgan Conference Presentation - Detailed data from the BLU-808 Phase 1 trial will be presented at the J P Morgan conference on January 13, 2025 [1][9] - The CEO will present a company overview and 2025 outlook at the conference, with a live webcast available on the company's website [9]

CAMBRIDGE, Mass., Dec. 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland, Chief Executive Officer, will present a corporate overview and 2025 outlook at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 9:00 a.m. PT (12:00 p.m. ET). A live webcast of the presentation will be available by visiting the Investors & Media section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. A replay of the webcast wi ...

It has been about a month since the last earnings report for Blueprint Medicines (BPMC) . Shares have added about 8.7% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Blueprint Medicines due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. BPMC Beats on Q3 Earnings and S ...

Blueprint Medicines Corporation (BPMC) reported third-quarter 2024 adjusted loss of 89 cents per share, narrower than the Zacks Consensus Estimate of a loss of 97 cents. The company had incurred a loss of $2.20 per share in the year-ago quarter.Quarterly revenues of $128.2 million, generated entirely from the net product sales of Ayvakit, surpassed the Zacks Consensus Estimate of $126 million. Total revenues jumped 127% year over year. Ayvakit sales have increased 136% year over year, driven by new patient ...